Literature DB >> 14377276

Treatment of chronic schizophrenic reactions with reserpine.

L E HOLLISTER, G E KRIEGER, A KRINGEL, R H ROBERTS.   

Abstract

Entities:  

Keywords:  RAUWOLFIA ALKALOIDS/therapeutic use; SCHIZOPHRENIA/therapy

Mesh：

Substances：

Year:  1955        PMID： 14377276     DOI： 10.1111/j.1749-6632.1955.tb42455.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  8 in total

1.  Reserpine, gastric secretion, and peptic ulcer.

Authors:  W H BACHRACH
Journal:  Am J Dig Dis       Date:  1959-02

2.  Experiments on the site of action of tubocurarine when applied via the cerebral ventricles.

Authors:  W FELDBERG; J MALCOLM
Journal:  J Physiol       Date:  1959-12       Impact factor: 5.182

3.  Chlorpromazine alone and with reserpine; use in the treatment of mental diseases.

Authors:  L E HOLLISTER; K P JONES; B BROWNFIELD; F JOHNSON
Journal:  Calif Med       Date:  1955-09

4.  Thioridazine (mellaril) in psychiatric patients.

Authors:  L E HOLLISTER; B F MACDONALD
Journal:  Calif Med       Date:  1959-11

5.  Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.

Authors:  A Wolkin; E Duncan; M Sanfilipo; S Wieland; T B Cooper; J Rotrosen
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  [The Rauwolfia alkaloid, reserpine (serpasil) in psychiatry].

Authors:  F A MIELKE
Journal:  Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr       Date:  1956

7.  The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

Authors:  Oliver D Howes; Joseph Kambeitz; Euitae Kim; Daniel Stahl; Mark Slifstein; Anissa Abi-Dargham; Shitij Kapur
Journal:  Arch Gen Psychiatry       Date:  2012-08

Review 8.  Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

Authors:  I Bonoldi; O D Howes
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.